Home › Funds › Tandem Investment Advisors, Inc. › ABT

Tandem Investment Advisors, Inc. position in ABT

ABBOTT LABORATORIES · Health Care

Tandem Investment Advisors, Inc. reported holding 392,377 shares of ABT (ABBOTT LABORATORIES) in its Q3 2026 13F filing — a position valued at US$38.8M, representing 2.89% of its reported portfolio and ranking #15 among its reported holdings. Tandem Investment Advisors, Inc. has disclosed ABT holdings in 13 of the last 13 reported quarters, going back to Q3 2023.

Latest position (Q3 2026)392.38K sh
Reported value held$38.78M
Portfolio Weight2.89%
First reportedQ3 2023
Last changeReduce
Updated2026-11-13

Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR

How Tandem Investment Advisors, Inc.'s ABT position evolved

Tandem Investment Advisors, Inc. first disclosed a stake in ABT in Q3 2023 at 963,354 shares (US$93.3M). The position peaked in Q2 2025 at 992,763 shares, worth US$135.0M. Across 13 filings, Tandem Investment Advisors, Inc. increased the stake 3 time(s), trimmed it 5 time(s) and left it unchanged 4 time(s). The most recent filing (Q3 2026) shows 392,377 shares valued at US$38.8M — a reduction of -84,176 shares quarter over quarter.. Notable position changes include a 36% trim in Q1 2026 (shares fell 11% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q3 2023 963.35K $93.30M New
Q4 2023 916.54K $100.88M Reduce
Q1 2024 964.08K $109.58M Add
Q2 2024 996.33K $103.53M Add
Q3 2024 992.41K $113.14M Hold
Q4 2024 992.60K $112.27M Hold
Q1 2025 987.57K $131.00M Reduce
Q2 2025 992.76K $135.03M Add
Q3 2025 992.66K $132.96M Hold
Q4 2025 992.84K $124.39M Hold
Q1 2026 630.60K $64.74M Reduce
Q2 2026 476.55K $43.24M Reduce
Q3 2026 392.38K $38.78M Reduce

Dots on the line are colored by change type; missing quarters mean no position was reported.

About ABT and 13F data

ABT (ABBOTT LABORATORIES) is a Health Care company. 21 other funds we track also report a position in ABT — the largest reported positions include Vanguard Group (US$22.00B), Charles Schwab Investment Management (US$5.41B), CHARLES SCHWAB INVESTMENT MANAGEMENT INC (US$5.41B). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding ABT

All ABT fund holders →

FAQ

How long has Tandem Investment Advisors, Inc. held ABT?

Tandem Investment Advisors, Inc. has disclosed ABT holdings in 13 of the last 13 reported quarters, going back to Q3 2023.

What is Tandem Investment Advisors, Inc.'s current position in ABT?

As of Q3 2026, Tandem Investment Advisors, Inc. holds 392.38K shares of ABT (ABBOTT LABORATORIES), valued at $38.78M, representing 2.89% of its reported portfolio and ranking #15.

Has Tandem Investment Advisors, Inc. been buying or selling ABT?

In the latest 13F filing (Q3 2026), Tandem Investment Advisors, Inc. reduced its position in ABT. The position peaked in Q2 2025 at 992.76K shares.

Which other funds hold ABT?

Other major institutional holders of ABT include Vanguard Group, Charles Schwab Investment Management, CHARLES SCHWAB INVESTMENT MANAGEMENT INC, among 21 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.